6334-11-8

Usage

Safety Profile

Suspected carcinogen with experimental carcinogenic and neoplastigenic data. Poison by intraperitoneal route. Moderately toxic by ingestion. When heated to decomposition it emits very toxic fumes of NOx and HCl.

InChI:InChI=1/C9H13N.ClH/c1-6-4-7(2)9(10)8(3)5-6;/h4-5H,10H2,1-3H3;1H

Upstream product

• 88-05-1 2,4,6-trimethylaniline 
• 124862-47-1 azidotri-2,4,6-trimethylphenylgermane 

Downstream Products

• 95074-43-4 1-mesityl-biguanide; hydrochloride 
• 790689-27-9 N-(2,4,6-trimethyl-phenyl)-guanidine hydrochloride 
• 25364-44-7 N-(2,4,6-trimethylphenyl)imidazole 
• 70335-45-4 2,4,6-trimethylphenyl diazonium chloride 
• 5897-07-4 Di-B-chlor-tri-N-mesityl-borazol 
• 46167-49-1 Mesityl-guanidin 
• 527-60-6 Mesitol 
• 87-85-4 Hexamethylbenzene 
• 488-71-1 2,3,4,6-tetramethylaniline 

Relevant academic research and scientific papers

Heterocyclic derivatives as CRF antagonists

This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I wherein X1 is (CH2)n or CO, n is 0 to 2 and R1, R2, R3 and R4

N-Mesityl dimesitylgerma-imine

N-Mesityldimesitylgermaimine (1) which is obtained by photolysis of trimesitylgermylazide has also been detected in the reaction of dimesitylgermylene with mesitylazide. 1 was characterized at room temperature by its pseudo-Wittig reaction with benzaldehy

1,3-Diaryl-2-imino-imidazolidines and compositions thereof

The invention relates to new compounds of the general formula (I), STR1 wherein R1 and R5 each represent a phenyl group, optionally substituted, R2 stands for hydrogen, formyl group, carboxy group, lower alkoxycarbonyl gro